The Long-Acting Cabotegravir Tail as an Implementation Challenge: Planning for Safe Discontinuation

AIDS Behav. 2023 Jan;27(1):4-9. doi: 10.1007/s10461-022-03816-0. Epub 2022 Sep 3.

Abstract

The long-acting feature of cabotegravir, an integrase-inhibitor highly effective in preventing acquisition of HIV in adolescents and adults, is both its greatest strength and a challenge to its implementation. Cab-LA is administered at 8-week intervals (after an initial loading dose) but has a long, variable drug "tail" that may leave users vulnerable to future drug resistance if they contract HIV during this critical period. The potential for cab-LA to meaningfully contribute to ending the HIV Epidemic is hindered by, among other factors, limited resources to guide patients and providers on how to safely discontinue injections. We suggest three key strategies to overcome this specific challenge: (1) Comprehensive patient education and counseling about the drug tail; (2) Training and coaching PrEP care teams, including clinical and non-clinical staff, on communication around the tail; (3) Adherence support strategies, including monitoring of cabotegravir drug levels after discontinuation, for a personalized medicine approach to safe discontinuation.

Keywords: PrEP; cabotegravir; drug level monitoring; implementation.

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • HIV Integrase Inhibitors*
  • Humans
  • Pre-Exposure Prophylaxis*

Substances

  • Anti-HIV Agents
  • cabotegravir
  • HIV Integrase Inhibitors